1. Introduction {#s0005}
===============

Embryonal tumors are highly malignant neoplasms with a propensity for spread along the craniospinal axis that primarily affect young children. In 2000, Eberhart [@b0005], described a set of embryonal tumors with very poor prognosis occurring primarily in young children characterized by abundant neuropil and true "ependymoblastic" rosettes. These tumors became known as embryonal tumors with abundant neuropil and true rosettes (ETANTR).

ETANTR have unique molecular features, including 19q13.42 amplification (microRNA cluster C19MC) and LIN28A positivity, that are associated with tumorigenesis, aggressive behavior and poor survival [@b0010], [@b0015], [@b0020], [@b0025], [@b0030], [@b0035], [@b0040]. Multiple groups have reported that ETANTRs, ependymoblastoma (EPL), and medulloepithelioma (MEP) comprise the same molecular entity characterized by normal INI-1 nuclear staining, LIN28A protein positivity, and C19MC microRNA cluster amplification at Chr19q13.41--42 [@b0010], [@b0015], [@b0035], [@b0040], [@b0045], [@b0050]. The umbrella term, embryonal tumor with multilayered rosettes (ETMR), was suggested to encompass these entities [@b0055]. In the 2016 World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS), embryonal tumor with multilayered rosettes, C19MC-altered (ETMR) was added to the classification of CNS embryonal tumors [@b0060].

Patients with ETMR have a dismal prognosis [@b0065], [@b0070]. Despite aggressive multi-modality intervention, median overall survival (OS) is 12 months or less, with a median age at diagnosis of 2 years or less [@b0035], [@b0040].

Due to the rarity of these tumors, the optimal treatment approach has not been defined. Based on treatment of other embryonal tumors, an age-adapted multimodality approach is used, generally involving maximal safe resection, age and risk adapted radiotherapy, and chemotherapy. Emerging evidence in AT/RT, an aggressive embryonal tumor with similarly bleak OS, supports early radiation even in younger patients to improve disease control and long term-survival [@b0075], [@b0080], [@b0085], [@b0090], [@b0095]. For patients at least 3 years of age, craniospinal irradiation (CSI) is often used given the propensity of these tumors to disseminate along the craniospinal axis.

Proton therapy has attracted significant interest in the treatment of pediatric malignancies due to its potential to decrease late effects and lower the risk of secondary malignancies [@b0080]. In patients treated with craniospinal irradiation (CSI), the use of proton therapy compared to standard photon therapy effectively eliminates dose to the heart, lungs, and bowel [@b0100], [@b0105], [@b0110], [@b0115], [@b0120], [@b0125], [@b0130], [@b0135], [@b0140], [@b0145], [@b0150], [@b0155], [@b0160], [@b0165], [@b0170], [@b0175].

The aim of this study was to evaluate a single institution experience in the use of proton therapy for the treatment of ETMR. We also reviewed the published peer-reviewed literature to evaluate the role of radiotherapy in the treatment of patients with ETMR.

2. Materials and methods {#s0010}
========================

Most patients treated with proton therapy at MD Anderson Cancer Center (Houston, TX) are enrolled on a prospective registry protocol to study outcomes and normal tissue toxicities. We searched this database and identified patients with EPL, MEP, ETANTR, or ETMR treated with proton therapy. Their medical records were retrospectively reviewed for clinical data, treatment details, and outcomes. Pathology was reviewed at MD Anderson or Texas Children's Hospital before radiotherapy. All seven cases were evaluated by routine hematoxylin and eosin (H&E) stains and immunohistochemistry. The extent of surgical resection was defined as gross total resection (GTR, no residual tumor), near total resection (NTR, \<10% residual tumor), subtotal resection (STR, \>10% residual tumor), or biopsy only based on analysis of the post-operative MRI and intraoperative impression of the attending neurosurgeon. Patients underwent brain and spine MRI as well as CSF analysis prior to radiotherapy. Metastatic disease was staged according to modified Chang criteria [@b0180].

All patients were treated with passive scatter proton therapy as previously described [@b0080], [@b0185]. For craniospinal radiation (CSI), the brain was treated with opposed oblique fields and the spine was treated with two posterior-anterior fields. Junctions between fields were 1 cm apart and shifted every 4--5 fractions. The entire vertebral body was treated in all patients due to their young age. Doses were prescribed in cobalt-60 Gy equivalents (GyRBE) using a relative biological effectiveness value of 1.1 relative to photons per ICRU 78 [@b0190]. All treatment was delivered at 1.8 GyRBE per fraction. The gross tumor volume (GTV) included the resection cavity and any residual disease as determined by imaging or neurosurgical impression. The clinical tumor volume (CTV) was defined by an anatomically constrained 1 cm volumetric expansion of the GTV. Planning and uncertainty margins were added for each beam as previously described [@b0120]. All patients required anesthesia for simulation and treatment.

We used PubMed to search the published peer-reviewed literature. Search terms included EPL, MEP, ETANTR, ETMR, CNS, cerebrum, cerebral, and spine. EPLs and MEPs of the optic nerve, intraocular, pelvic, peripheral, and pre-sacral regions were excluded because of their molecular diversity compared with intracranial ETMRs^.^[@b0060] No language restrictions were used. All full-length articles were obtained and demographic, treatment, and survival data were gathered when available.

3. Results {#s0015}
==========

3.1. MD Anderson cases {#s0020}
----------------------

Details of patients treated with proton therapy at MD Anderson are summarized in [Tables 1](#t0005){ref-type="table"} and [2](#t0010){ref-type="table"}. Seven patients with ETMR were identified, 5 boys and 2 girls, with a median age at diagnosis of 33 months (range 10--57 months). The median age at radiation start was 42 months (range, 17--58 months). Six patients had infratentorial primary disease (86%) and one patient had a supratentorial tumor (14%). All seven patients had M0 disease at initial diagnosis, but one was M3 by the start of radiation (Pt. \#5, [Table 1](#t0005){ref-type="table"}).Table 1Patient characteristics, treatments, and outcomes.Pt \#Age at Dx (mo)GenderLocationProtocolStageSurgeryAge at RT (mo)PD before RTCSI dose (GyRBE)Tumor bed dose (GyRBE)Site of recurrence after RTLast statusOS from Dx (mo)133FLeft frontal lobeSJYC07 [@b0525]M0NTR42Local and distant3650.4AWSD64233FPonsHead Start III [@b0530]M0STR36Local3654Pons, spineDOD16341MPonsSJMB 03 [@b0535]M0GTR44Local3655.8DOC^1^11457ML-spineACNS 0332 [@b0540]M0GTR58Local and distant3652.2NED44526MCPANoneM0GTR32Local and distant3654 (PF), 45 (spine)DOC^2^13649MPonsACNS 0332 [@b0540]M0Bx51No054AWSD8710MCPACCG-99703 [@b0545]M0STR17No050.4NED36[^1]Table 2Systemic therapy.Pt. \#ProtocolSystemic therapy before RTSystemic therapy with RTSystemic therapy after RT1SJYC07 [@b0525]HDC×4 cycles with MTX, VCR, VLB, CYC and CDDP then TPT×2 cycles, followed by CYC maintenanceCDDP with VPAMetronomic chemotherapy: VP-16, TMZ, VPA, CRA, MET, MLT×6 cycles2Head Start III [@b0530]CDDP, VP-16, VCR, CYC, and HD MTX followed by a cycle of VP-16, TMZNoneMC (VPA, MLT, and MET) and VP-16, TMZ, CRA3SJMB 03 [@b0535]VCR, CDDP, and CYC×2 cyclesNoneNone4ACNS 0332 [@b0540]NoneVCR and CDDPHD CDDP, VCR, CYC^1^ with ASCT. Switched to MC (ISO, MET, MLT, VPA, VP-16, TMZ, CRA, CYC, and celecoxib)5NoneIFO, VP-16, and VCR×3 cyclesNone2× cycles HD CDDP/THIO with ASCT6ACNS 0332 [@b0540]Vorinostat, CRACDDP and VCRNone7CCG-99703 [@b0545]CDDP, VCR, CYC, VP-16×3 cycles, then CDDP/THIO×3 cycles followed by SCTNoneNone[^2]

Three patients had GTR, one had NTR, two had STR, and one had biopsy only. Six patients received chemotherapy after surgery and before radiation ([Table 2](#t0010){ref-type="table"}). Chemotherapy was delivered according to various protocols as detailed in [Table 2](#t0010){ref-type="table"}. Five patients had progressive disease (PD) before radiation ([Table 1](#t0005){ref-type="table"}). All five of these patients progressed in the tumor bed; three also had distant CNS progression prior to radiation.

Two patients received focal radiation to the tumor bed (Pts. \#6 and 7) to 50.4 GyRBE and 54 GyRBE. Five patients received CSI (Pts. 1--5), all to a dose of 36 GyRBE. For the patients who received CSI, the median dose to the primary tumor was 53.1 GyRBE (range, 45--55.8 GyRBE).

Radiation was well tolerated with minimal acute toxicities. Regarding long term toxicities, two patients developed endocrinopathies. One patient remained within the lowest 25% quartile of stature for his age with borderline normal IGF-1 (Pt. \#7, not yet on growth hormone therapy) by 2.5 years after completing therapy, and one patient required cortisol replacement therapy 53 months after proton therapy (Pt. \#1).

The median follow-up was 40 months for surviving patients. At a median OS of 16 months (range, 8--64 months) for all patients, four of seven patients (57%, crude rate) were alive without evidence of disease progression, and three patients (43%, crude rate) died. The causes of death for these three patients were cardiac arrest due to sepsis during chemotherapy after radiotherapy, disease progression, and unknown.

3.2. Review of the literature {#s0025}
-----------------------------

ETMRs have been reported in the literature as EPL, MEP, and ETANTR. Due to the rarity of these tumors, descriptions are often found in individual case reports or small case series in the literature. Since the first report of ETANTR in 2000 [@b0005], some ETMRs were reported as EPL and MEP. This review focuses on MEP, EPL, and ETANTR of the CNS. Cases of MEP and EPL outside the CNS were excluded; these included cases with primary sites in the ovary [@b0195], [@b0200], sacrococcygeal region [@b0205], [@b0210], pelvis [@b0215], [@b0220], optic nerve [@b0225], [@b0230], intraocular [@b0235], and sciatic nerve [@b0240].

A search of the peer reviewed literature published since 1990 yielded 204 cases of ETMR. Other authors have reviewed cases of MEP and EPL described since the 1920s to 1990 [@b0225], [@b0245], [@b0250], [@b0255]. The patient characteristics, treatment, and outcome of these 204 cases plus the seven MD Anderson cases are summarized in [Table 3](#t0015){ref-type="table"}[@b0005], [@b0025], [@b0035], [@b0045], [@b0070], [@b0245], [@b0250], [@b0255], [@b0260], [@b0265], [@b0270], [@b0275], [@b0280], [@b0285], [@b0290], [@b0295], [@b0300], [@b0305], [@b0310], [@b0315], [@b0320], [@b0325], [@b0330], [@b0335], [@b0340], [@b0345], [@b0350], [@b0355], [@b0360], [@b0365], [@b0370], [@b0375], [@b0380], [@b0385], [@b0390], [@b0395], [@b0400], [@b0405], [@b0410], [@b0415], [@b0420], [@b0425], [@b0430], [@b0435], [@b0440], [@b0445], [@b0450], [@b0455], [@b0460], [@b0465], [@b0470], [@b0475], [@b0480], [@b0485], [@b0490].Table 3Patient characteristics, treatment, and outcomes of ETMR (ETANTR, MEP, EPBL) cases described in the literature.No (%) TOTALNo (%) EPBLNo (%) MEPNo (%) ETANTR*Age (months)*0--1229 (14)4 (13)5 (20)20 (12.9)\>12--2468 (32)6 (19)7 (28)55 (35.5)\>24--3655 (26)9 (29)5 (20)41 (26.5)\>36--4835 (16.6)6 (19)3 (12)26 (16.8)\>48--6010 (4.8)2 (7)2 (8)6 (3.8)\>6014 (6.6)4 (13)3 (12)7 (4.5)  *Gender*Males97 (46)20 (65)12 (48)65 (42)Females105 (50)10 (32)5 (20)90 (58)Unreported9 (4)1 (3)8 (32)0  *Primary tumor location*Supra-tentorial130 (61.6)16 (52)17 (68)97 (62.6)Infra-tentorial73 (34.6)14 (45)7 (28)52 (33.5)Supra and Infra-tentorial4 (1.9)01 (4)3 (1.95)Unreported4 (1.9)1 (3)03 (1.95)  *M Stage*MX96 (45.5)11 (35.2)11 (44)74 (47.7)M087 (41.2)17 (54.8)9 (36)61 (39.4)M16 (3)1 (3.33)4 (16)1 (0.65)M23 (1.5)1 (3.33)1 (4)1 (0.65)M319 (8.8)1 (3.33)018 (11.6)M40000  *Initial treatment*None3 (1.4)03 (12)0Surgery (S)35 (16.6)7 (22)8 (32)20 (12.9)Chemotherapy (C)9 (4.3)009 (5.8)Radiotherapy (RT)1 (0.4)01 (4)0S, C78 (37)10 (32)4 (16)64 (41.3)S, RT3 (1.4)1 (5)02 (1.3)RT, C5 (2.4)01 (4)4 (2.7)S, C, RT56 (26.5)7 (22)7 (28)42 (27)Unknown21 (10)6 (19)1 (4)14 (9)  *Outcome (n = 178)*Unknown^\*^33^\*^6225Mean survival time19.3 (median 10, 0.03--183.9 range)22.519.718.7Alive55 (30.9)6 (24)4 (17)45 (34.6)Dead123 (69.1)19 (76)19 (83)85 (65.4)DOD117 (65.7)17 (68)16 (70)84 (64.6)DOC6 (3.4)2 (8)3 (13)1 (0.8)NED27 (15.2)4 (16)1 (4)22 (16.9)RPD10 (5.6)0010 (7.7)AWSD18 (10.1)2 (8)3 (13)13 (10)[^3]

For all 211 reported cases, the female: male ratio was 1.08:1. The majority of tumors were supratentorial (62%). The most commonly involved primary sites were the frontal lobe, cerebellum, and brainstem. Less commonly, cases involved the parietal lobe, temporal lobe, occipital lobe, pineal region, sella turcica, basal ganglia, thalamus, 4th ventricle, 3rd ventricle, lateral ventricles, and spine.

The median age at presentation was 27.6 months (range 0.5--216 months). Symptoms depended on the location of the tumor and included headache, vomiting, cranial nerve deficits, ataxia, weakness and paralysis. Likewise, imaging characteristics were variable. Tumors were often solid with cystic and calcified components with or without enhancing portions on post-contrast imaging. Metastatic stage was not reported in 96 cases (45.5%). In the 115 cases where M-stage was available, 87 (76%) patients had M0 disease, 6 (5%) had M1 disease, 3 (3%) had M2 disease, and 19 (17%) had M3 disease ([Table 3](#t0015){ref-type="table"}).

The most common treatment was a trimodality approach with surgery, chemotherapy, and radiation (56 of 211 patients, 26.5%). The extent of resection was reported as GTR in 54 cases, NTR in 6 cases, STR in 57 cases, and unknown in 53 cases; 3 patients did not receive any treatment, 21 cases (10%) did not report treatment, and 17 patients received biopsy only. Most patients, 156 of 211 (74%) received chemotherapy ([Table 3](#t0015){ref-type="table"}).

Sixty-five of 211 (31%) patients received radiation, which was typically avoided in patients less than three years old. The majority of patients in the literature were treated with photons. Two patients in the literature were treated craniospinal proton therapy [@b0045], [@b0340].

Follow up information was available for 178 patients. Median OS was 10 months after initial diagnosis (range 0.03--183.9). At last follow up, 123 (69%) were dead and 55 (31%) were alive. The resection cavity was the most common site of disease recurrence, followed by the spine, which is consistent with the patterns of failure of PNETs [@b0495], [@b0500].

Only 18 patients have been reported who are long-term survivors (≥36 months) with a median age at diagnosis of 35.4 months (range 7--139.2 months), and a median OS of 77.25 months (range 37.2--183.9 months) [@b0035], [@b0250], [@b0275], [@b0330], [@b0335], [@b0345], [@b0390], [@b0400]. Sixteen of these eighteen patients received trimodality therapy with surgery, chemotherapy and radiotherapy; one patient received surgery and chemotherapy [@b0275], and one received surgery and radiation [@b0345]. Therefore, 94% of long-term survivors (17 of 18) in the literature received radiotherapy as part of their primary treatment [@b0275]. Fourteen of these patients received CSI with tumor bed boost, one received local radiation only, and two had unknown radiation treatment volumes. Treatment and outcomes of long-term survivors from the literature are summarized in [Table 4](#t0020){ref-type="table"}.Table 4Treatment and outcomes of long Term Survivors (≥36 months) in literature.Age (mo)Loc.TreatmentXRT detailsChemoOutcomeOSRef15CS (GTR), C, RT20 Gy CSI + 26 Gy TBBIT MTX×3NED161[@b0250]17RTPS (GTR), C, RT55 Gy LFVCR, VP-16, CDDP, CYC, CPNED44[@b0250]36LFS, C, RTUnknownUnknownNED42[@b0005], [@b0335]67.2LFTS (GTR), C, RT35.2 Gy CSI, 20 Gy TBBPer HIT91NED152.4[@b0330]40.8LPS (GTR), C, RT35.2 Gy CSI, 20 Gy TBBPer HIT91NED112.8[@b0330]67.2RFPS (GTR), C, RT36 Gy CSI, 30 Gy TBBPer HIT SKK2000DOD37.2[@b0330]48RPS (GTR), C, RT35.8 Gy CSI, 19.9 Gy TBBCP, VCR, CYC, CDDPNED84[@b0390]7LTPS (GTR), CNoneVCR, CDDP, VP-16, CYC, MTXNED48[@b0275]23STS, C, RTUnknownUnknownAlive56[@b0035]138STS (GTR), RTCSI + TBB^1^NoneNED183.9[@b0345]34.8SCS (GTR), C, RTCSI + TBB^1^VPCP×2, HDCNED43.2[@b0345]26.4STS (GTR), C, RTCSI + TBB^1^VPCP×2, HDCNED143.6[@b0345]38.4STS (STR), C, RTCSI + TBB^1^VPCP×2, HDCAWSD90.9[@b0345]81.6STS (GTR), C, RTCSI + TBB^1^VPCP×2, MP + CDDP×2NED63.8[@b0345]24STS (STR), C, RTCSI + TBB^1^VPCP×2, MP×2, THIO×2NED143.4[@b0345]31.2ITES (GTR), C, RTCSI + TBB^1^VPCP×2, HCDNED103.3[@b0345]139.2ITES, C, RTCSI + TBB^1^VPCP×2, THIO×2, TMZ×2NED70.5[@b0345]24LC, LOS (GTR), C, RT32 Gy CSI, 24 Gy TBBHRP + IT VCR, CDDP, VP-16NED52[@b0400][^4]

4. Discussion {#s0030}
=============

This report summarizes treatments and outcomes of 211 patients with ETMR described since 1990. This is the largest series focusing on the use of radiotherapy in ETMR, and the only series detailing long-term survivors treated with proton therapy. Our review suggests that the use of early radiotherapy in ETMR may contribute to long-term survival. Of 18 long-term survivors in the literature, 17 received radiotherapy as part of their treatment ([Table 4](#t0020){ref-type="table"}). Of seven patients treated at MD Anderson with proton therapy, three survived 36 months or longer from diagnosis ([Table 1](#t0005){ref-type="table"}).

Multiple authors have reported a statistically significant OS benefit in ETMR with the addition of radiotherapy. Alexiou et al. [@b0275] reported that ETANTR patients treated with radiotherapy had a statistically significant improved OS compared to patients who did not receive radiotherapy. Similarly, Ding [@b0245] found that the addition of radiotherapy, chemotherapy or combined chemo-radiotherapy had a significant survival benefit compared to patients who did not receive radiotherapy, chemotherapy or combined post-operative chemo-radiotherapy. Horwitz reported a statistically significant OS benefit on multivariate analysis of patients who received complete surgical resection, radiotherapy and high dose chemotherapy [@b0345]. In a series of 11 EPL patients treated on the prospective HIT-trials [@b0330], the only two long-term survivors (follow up of 12.7 and 9.4 years, respectively) received CSI therapy with involved field boost as part of their first line-therapy; a third patient who received radiation had stable disease at 2.3 years.

Due to the very young patient population of ETMR, with a median age at diagnosis of 2 years, there is often hesitation to administer radiotherapy due to concern for late effects. There is considerable interest in using proton therapy to reduce unnecessary radiation exposure compared to photon-based radiotherapy. For patients treated with CSI, the use of proton therapy reduces acute hematologic and gastrointestinal side effects [@b0505]. For patients treated with focal fields in the brain or spine, proton therapy decreases the low-dose exposure of adjacent, uninvolved brain parenchyma and spinal cord. By minimizing radiation dose to critical structures such as the hippocampi and hypothalamus, proton therapy may decrease the risk of late effects, including endocrine deficiencies [@b0510] and secondary malignancies [@b0080], [@b0185]. In particular, the use of proton therapy may decrease neurocognitive deficits in patients treated with focal radiation fields [@b0515], [@b0520]. The youngest patient treated in our institutional series was 17 months old at the time of radiotherapy and was alive without evidence of disease recurrence 36 months after diagnosis (Pt. \#7).

Optimal radiation volumes remain poorly defined in ETMR. In our institutional series, all seven patients had M0 disease at diagnosis; five of these patients developed recurrence within the resection cavity and three of those five patients had CNS spread in 1--11 months prior to radiation. Based on the North American approach to other embryonal tumors, CSI may be considered for patients older than three years of age. Notably, the European approach to AT/RT on the current EU-RHAB protocols includes focal radiation for patients with M0 disease. Results from the St. Jude's and COG trials in AT/RT are awaited to better define radiation volumes in these young patients with very aggressive CNS embryonal tumors.

5. Conclusions {#s0035}
==============

ETMR is an aggressive embryonal tumor occurring in young children with a historic OS of 10 months. Based on the treatment of other CNS embryonal tumors, the treatment of ETMR typically consists of maximal safe surgery, chemotherapy and radiotherapy. Due to the very young age of these patients, radiation is often delayed or avoided. This comprehensive literature review and our institutional experience suggest that early radiotherapy may improve outcomes in ETMR. The use of proton therapy to reduce acute and long term effects may facilitate the use of radiation in these young patients.
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The following are the Supplementary data to this article:Supplementary Data 1

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ctro.2018.11.002>.

[^1]: Pt. \# = Patient number, RT = radiotherapy, mo = months, PD = progressive disease, AWSD = alive with stable disease, DOD = died of disease, DOC = died of other or unknown cause, NED = no evidence of disease, Gy (RBE) = cobalt-60 Gy equivalents, CSI = craniospinal irradiation, GTR = gross total resection, NTR = near total resection, STR = subtotal resection, Bx = biopsy only, CPA = cerebellopontine angle, ^1^unknown cause of death, ^2^Patient was M3 at start of radiation with gross disease to the spine, died of cardiopulmonary arrest secondary to sepsis.

[^2]: Pt. \# = Patient number, RT = radiotherapy, ASCT = autologous stem cell transplant, ^1^aborted due to hearing loss with cisplatin, HDC = high dose chemotherapy, MC = metronomic chemotherapy, MTX = methotrexate, VCR = vincristine, VLB = vinblastine, CYC = cyclophosphamide, CDDP = cisplatin, TPT = topotecan, VPA = valproic acid, VP-16 = etoposide, TMZ = temozolomide, CRA = cis-retinoic acid, MET = metformin, MLT = melatonin, ISO = isotretinoin, IFO = ifosfamide, THIO = thiotepa (THIO).

[^3]: Table includes the 7 cases treated at MD Anderson. S = surgery, C = chemotherapy, RT = radiotherapy, DOD = died of disease, DOC = died of other, NED = no evidence of disease, AWSD = alive with stable disease, RPD = recurrent progressive disease, ^\*^33 cases did not report outcome, not included in percentage calculation. Compiled from references: [@b0005], [@b0025], [@b0035], [@b0045], [@b0070], [@b0245], [@b0250], [@b0255], [@b0260], [@b0265], [@b0270], [@b0275], [@b0280], [@b0285], [@b0290], [@b0295], [@b0300], [@b0305], [@b0310], [@b0315], [@b0320], [@b0325], [@b0330], [@b0335], [@b0340], [@b0345], [@b0350], [@b0355], [@b0360], [@b0365], [@b0370], [@b0375], [@b0380], [@b0385], [@b0390], [@b0395], [@b0400], [@b0405], [@b0410], [@b0415], [@b0420], [@b0425], [@b0430], [@b0435], [@b0440], [@b0445], [@b0450], [@b0455], [@b0460], [@b0465], [@b0470], [@b0475], [@b0480], [@b0485], [@b0490].

[^4]: S = surgery, C = chemotherapy, RT = radiotherapy, CSI = craniospinal irradiation, GTR = gross total resection, STR = subtotal resection, TBB = tumor bed boost, LF = local field, NED = no evidence of disease, DOD = died of disease, AWSD = alive with stable disease, IT = intrathecal, R = right, L = left, T = Temporal, P = parietal, F = frontal, C = cerebellum, O = occipital, ST = supratentorial, ITE = infratentorial, SC = spinal cord, MP = melphalan, VP-16 = etoposide, THIO = thiotepa, VPCP = VP-16 + CP, CP = carboplatin, CDDP = cisplatin, VCR = vincristine, CYC = cyclophosphamide, TMZ = temozolomide, HDC = MP + CDDP + THIO, HRP = 2× VCR + CYC + VP-16 → 2× VCR + CP + VP-16 → 2× VCR + CDDP + VP-16 → IT triplet ×7, ? = unspecified, ^1^ per protocol in Ref. [@b0550].
